Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (November 2023)
13 slides from Chimeric Therapeutics's shareholder meeting presentation, Nov 14, 2023
Slide 1: Bringing the Promise of Cell Therapy to Life
BRINGING THE For personal use only PROMISE OF CELL THERAPY TO LIFE Chimeric Therapeutics AGM 14 November 2023
Slide 2: Disclaimer
DISCLAIMER For personal use only Certain statements contained in this presentation, including, information or studies to be completed or provided prior to their without limitation, statements containing the words “believes,” approval of our products. “plans,” “expects,” “anticipates,” and words of s
Slide 3: Positive Phase 1 results and advancing clinical development
2 CLINICAL TRIALS WITH ADVANCING CLINICAL POSITIVE PHASE 1 DEVELOPMENT RESULTS For personal use only • Positive CHM 1101 Phase 1A data in • Innovative cell therapy portfolio with 3 recurrent brain cancer novel technology platforms • Positive CHM 0201 Phase 1A data in • 4 ongoing clinical trials in s
Slide 4: Chimeric: A foundation for long term success, novel platform technologies
CHIMERIC: A FOUNDATION FOR LONG TERM SUCCESS 3 NOVEL PLATFORM TECHNOLOGIES For personal use only CHM 1101 CHM 2101 CHM 0201 (CLTX CAR T) (CDH17 CAR T) (CORE NK) 2020 2021 2022 2022 Best in class NK cell platform for First in class CDH17 CAR T Best in class NK cell platform for blood cancers and soli
Slide 5: CHM 1101: Positive Phase 1A clinical data in recurrent, late-stage brain cancer
5 CHM 1101: POSITIVE PHASE 1A CLINICAL DATA IN RECURRENT, LATE-STAGE BRAIN CANCER For personal use only DISEASE SURVIVAL SAFETY CONTROL RATE ~10 months Generally, well tolerated 55% Median survival in patients that achieved disease control • No Dose Limiting 14+ months Toxicities Disease Control Rat
Slide 6: CHM 2101: FDA IND Clearance
CHM 2101: FDA IND CLEARANCE A FIRST-IN-CLASS 3RD GENERATION CAR T FOR GASTROINTESTINAL TUMOURS For personal use only • FDA clearance for Chimeric IND for a Phase 1/ 2 clinical program in Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours CDH17 CAR T • First-in-class CAR T cell therapy lice
Slide 7: CHM 0201 for blood cancers and solid tumours
CHM 0201 for BLOOD CANCERS AND SOLID TUMOURS ADVANCING NOVEL PHASE 1B CLINICAL COMBINATIONS For personal use only CHM 0201 CHM 0201 + VACTO CHM 0201 + AZA/VEN Phase 1A Phase 1B Phase 1B COMPLETE TO ENROLLMENT ONGOING ENROLLMENT ENROLLMENT LATE 2023 Established Safety Initiated January 2023 FDA IND C
Slide 8: Value proposition for investors
VALUE PROPOSITION FOR INVESTORS For personal use only 1. 2. 3. ADVANCED, ADVANCING NAVIGATING UNDERVALUED DEVELOPMENT TO THE PORTFOLIO VALUE REALIZATION CHALLENGES Chimeric’s pipeline and Chimeric’s assets are Chimeric is responding to todays portfolio are highly entering Phase 1B, biotech environme
Slide 9: 1. Advanced, undervalued portfolio
1. ADVANCED, UNDERVALUED PORTFOLIO 3 Chimeric has an industry leading cell therapy portfolio with novel technology platforms in clinical stage development CHM Asset Tumour Type Discovery/ Preclinical Phase 1 Phase 2/ 3 For personal use only Recurrent/ Progressive COH Phase 1A Novel technology Gliobl
Slide 10: 2. Value realization opportunity focuses on Phase 1B
2. VALUE REALIZATION OPPORTUNITY FOCUSES ON PHASE 1B/ 2 CHIMERIC IS ADVANCING DEVELOPMENT TO BIG PHARMA’S FOCUS In today's market, big pharma M&A has shifted its focus from preclinical assets to assets that are clinically de-risked with Phase1A/B data For personal use only Chimeric currently has 3 o
Slide 11: 3. Navigating the challenges
3. NAVIGATING THE CHALLENGES To enable clinical advancement, Chimeric has responded to the challenges of todays market with program prioritization and cash preservation while creating value through business development For personal use only
Slide 12: Positive clinical data in GBM and AML
1 2 POSITIVE CLINICAL DATA in GBM and AML Two assets with positive Phase 1A clinical data ADVANCING CLINICAL DEVELOPMENT For personal use only Four ongoing clinical trials in solid tumours and blood cancers NEAR TERM MILESTONES Multiple clinical catalysts in next 12-18 months IMPACTFUL BUSINESS DEVE
Slide 13: Contact information
CONTACT INFORMATION For personal use only Jennifer Chow Chief Executive Officer and Managing Director Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com
Chimeric Therapeutics — Shareholder Meeting (November 2023) on 6ix